18F-fluoride PET/CT for bone scanning. Role of attenuation correction
- PMID: 22366817
- DOI: 10.3413/Nukmed-0433-11-10
18F-fluoride PET/CT for bone scanning. Role of attenuation correction
Abstract
Aim: 18F-fluoride PET/CT is a promising tool for bone scanning. Recently, guidelines concerning the conduct of 18F-fluoride PET/CT have been published. One open question of the German guideline was the necessity of attenuation correction for 18F-fluoride PET/CT. We evaluated the need for a CT-based attenuation correction in 18F-fluoride PET/CT scans for the detection of bone lesions.
Patients and methods: We retrospectively analyzed whole-body 18F-Fluoride PET/CT scans of 59 cancer patients. The lesions were categorized as malignant, benign or inconclusive. This assignment was performed for every lesion in both: attenuation corrected (AC) and non-attenuation-corrected (NAC) images. The maximum standardized uptake values (SUVmax) of the lesion in the AC images were also determined.
Results: All bone lesions were detected in both image modalities. The AC images revealed 201 lesions categorized as malignant, 114 as benign and 35 as inconclusive. Without an AC, the results were 209, 116 and 25, respectively (p > 0.05). 10/35 lesions categorized as inconclusive in the AC images were categorized as malignant in the NAC images, whereas 8 lesions were confirmed after comparison with other imaging modalities and follow-up data and 2 lesions were categorized as benign. The SUVmax for lesions identified as malignant showed a broad overlap with the SUV max of benign lesions and can consequently not be used for differentiation.
Conclusion: An AC is not necessary for detecting bone lesions on 18F-fluoride PET/CT scans as the detection capability is identical for NAC imaging and lesion assignment was even better than with AC imaging. SUVmax seems not to improve the differentiation between malignant and benign bone lesions.
Similar articles
-
Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.J Nucl Med. 2004 Feb;45(2):272-8. J Nucl Med. 2004. PMID: 14960647 Clinical Trial.
-
The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.J Nucl Med. 2006 Feb;47(2):287-97. J Nucl Med. 2006. PMID: 16455635
-
Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.J Nucl Med. 2009 Apr;50(4):520-6. doi: 10.2967/jnumed.108.054726. Epub 2009 Mar 16. J Nucl Med. 2009. PMID: 19289430
-
X-ray-based attenuation correction for positron emission tomography/computed tomography scanners.Semin Nucl Med. 2003 Jul;33(3):166-79. doi: 10.1053/snuc.2003.127307. Semin Nucl Med. 2003. PMID: 12931319 Review.
-
Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.Radiographics. 2014 Sep-Oct;34(5):1295-316. doi: 10.1148/rg.345130061. Radiographics. 2014. PMID: 25208282 Review.
Cited by
-
Comparison of standardized uptake values measured on F-NaF PET/CT scans using three different tube current intensities.Radiol Bras. 2015 Jan-Feb;48(1):17-20. doi: 10.1590/0100-3984.2014.0034. Radiol Bras. 2015. PMID: 25798003 Free PMC article.
-
(18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant Lesions.World J Nucl Med. 2016 May-Aug;15(2):102-8. doi: 10.4103/1450-1147.172301. World J Nucl Med. 2016. PMID: 27134560 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical